Since 2010, Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) has done at least 13 pipeline building deals. Nine were discovery or preclinical stage. Most recent deals at top. (A) JV between Kyowa and Amgen Inc. (NASDAQ:AMGN); Sources: BCIQ: BioCentury Online Intelligence; Kyowa Hakko Kirin

Partner/acquisition

Deal type

Description

Financials

Status at time of deal

Date

Adimab LLC

Research collaboration

Identify antibodies against two targets selected by Kyowa; initial focus on an undisclosed membrane protein target

Undisclosed research fees and technical milestones; Adimab eligible for undisclosed clinical milestones and royalties on antibodies licensed by Kyowa

Discovery/Preclin

Jan-13

NovAliX S.A.S.

Research collaboration

Use NovAliX's Graffinity fragment-based screening technology to discover and develop small molecules against undisclosed protein-protein interaction targets chosen by Kyowa

Undisclosed technology access fee, research funding, milestones

Discovery/Preclin

Jan-13